Related Experiment Video
Updated: May 29, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilar medicines and cost-effectiveness.
1Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium.
Clinicoeconomics and Outcomes Research : CEOR
|September 22, 2011
Summary
Economic evaluations for biosimilars are complex due to differing data needs for marketing and reimbursement. Assessing cost-effectiveness requires considering relative effectiveness and long-term data for accurate pricing.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Biotechnology
Background:
- Biosimilars are similar, not identical, to reference biopharmaceuticals.
- Economic evaluation compares costs and outcomes of medicines.
- Assessing biosimilar cost-effectiveness presents unique challenges.
Purpose of the Study:
- To introduce and describe issues in the economic evaluation of biosimilars.
- Focus on relative costs, effectiveness, and cost-effectiveness.
- Highlight discrepancies between regulatory and reimbursement data requirements.
Main Methods:
- Review of economic evaluation principles for pharmaceuticals.
- Analysis of data requirements for marketing authorization versus reimbursement.
- Discussion of methods for assessing cost-effectiveness based on evidence type (efficacy vs. effectiveness, endpoints).
Main Results:
- Marketing authorization evidence may not meet reimbursement authority needs (e.g., real-world data, health outcomes).
- Cost-minimization is possible if effectiveness is equivalent; otherwise, cost-effectiveness or cost-utility analyses are needed.
- Uncertainty in long-term safety and effectiveness necessitates multi-time point evaluations.
Conclusions:
- Economic evaluation of biosimilars is complex and depends heavily on relative effectiveness.
- Data requirements for regulatory approval and reimbursement differ, complicating assessments.
- Long-term safety and effectiveness data are crucial for accurate, lifecycle-based cost-effectiveness analysis.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.